In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA

BACKGROUND: Prostate-specific membrane antigen (PSMA) targeting radioligands have transformed treatment of prostate cancer. Radioligand therapy (RLT) with (177)Lu-PSMA in metastasized castration resistant prostate cancer (mCRPC) achieves objective response and disease stabilization in roughly two th...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Vikas, Huang, Kai, Prasad, Sonal, Makowski, Marcus R., Czech, Norbert, Brenner, Winfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010239/
https://www.ncbi.nlm.nih.gov/pubmed/33816225
http://dx.doi.org/10.3389/fonc.2021.578093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010239/
https://www.ncbi.nlm.nih.gov/pubmed/33816225
http://dx.doi.org/10.3389/fonc.2021.578093

Ejemplares similares